Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.61 |
| ▸ | ESR1 | P03372 | 9/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | PGR | P06401 | 2/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.48 |
| ▸ | AR | P10275 | 2/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.48 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | STS | P08842 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6465985 | 1.00 | LMNA (0.61) | LMNAHSD17B10ESR1SMN1; SMN2PGR | |
| SCHEMBL7885573 | 1.00 | LMNA (0.61) | LMNAHSD17B10ESR1SMN1; SMN2PGR | |
| SCHEMBL2356424 | 1.00 | LMNA (0.61) | LMNAHSD17B10ESR1SMN1; SMN2PGR | |
| SCHEMBL10800294 | 0.90 | LMNA (0.61) | LMNAHSD17B10ESR1SMN1; SMN2PGR | |
| SCHEMBL6463118 | 0.87 | LMNA (0.46) | LMNAHSD17B10ESR1SMN1; SMN2PGR | |
| SCHEMBL5353798 | 0.87 | LMNA (0.58) | LMNAHSD17B10ESR1SMN1; SMN2PGR | |
| SCHEMBL14559142 | 0.87 | LMNA (0.58) | LMNAHSD17B10ESR1SMN1; SMN2PGR | |
| SCHEMBL6466047 | 0.86 | LMNA (0.45) | LMNAHSD17B10ESR1SMN1; SMN2PGR | |
| SCHEMBL6853652 | 0.85 | LMNA (0.46) | LMNAHSD17B10ESR1SMN1; SMN2PGR | |
| SCHEMBL6465178 | 0.85 | LMNA (0.44) | LMNAHSD17B10ESR1SMN1; SMN2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6881728-B1 | 14-β, 17-α-hydroxymethylandrostane derivatives as androgens | AKZO NOBEL N.V. (NL) | 2005-04-19 | — | — | US | disclosed |
| US-6780854-B2 | MALE CONTRACEPTION | AKZO NOBEL NV (NL) | 2004-08-24 | — | — | US | disclosed |
| EP-1203011-B1 | ORALLY ACTIVE ANDROGENS | AKZO NOBEL NV (NL) | 2004-01-02 | — | — | EP | disclosed |
| US-6541465-B2 | Delta 14 derivatives of 19- nortestosterone, useful for the preparation of a medicine for treating androgen insufficiency | AKZO NOBEL N.V. (NL) | 2003-04-01 | — | — | US | disclosed |
| EP-1163259-B1 | 14.BETA.,17-ALPHA-HYDROXYMETHYLANDROSTANE DERIVATIVES AS ANDROGENS | AKZO NOBEL NV (NL) | 2002-11-20 | — | — | EP | disclosed |
| EP-1203011-A1 | ORALLY ACTIVE ANDROGENS | Akzo Nobel N.V. (NL) | 2002-05-08 | — | — | EP | disclosed |
| US-20020022609-A1 | Orally active androgens | LOOZEN HUBERT JAN JOZEF (NL) | 2002-02-21 | — | — | US | disclosed |
| US-6313108-B1 | TREATING ANDROGEN INSUFFICIENCY | AKZO NOBEL N.V. (NL) | 2001-11-06 | — | — | US | disclosed |
| WO-2001005806-A1 | ORALLY ACTIVE ANDROGENS | AKZO NOBEL N.V. (NL) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022609-A1 | Orally active androgens | NR5A1, AR, CYP17A1 | LMNA 2728/4885HSD17B10 41/4885ESR1 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.